MX2017008093A - Complejos radiofarmaceuticos. - Google Patents
Complejos radiofarmaceuticos.Info
- Publication number
- MX2017008093A MX2017008093A MX2017008093A MX2017008093A MX2017008093A MX 2017008093 A MX2017008093 A MX 2017008093A MX 2017008093 A MX2017008093 A MX 2017008093A MX 2017008093 A MX2017008093 A MX 2017008093A MX 2017008093 A MX2017008093 A MX 2017008093A
- Authority
- MX
- Mexico
- Prior art keywords
- chelator
- tissue
- tone
- complex
- directed
- Prior art date
Links
- 229940121896 radiopharmaceutical Drugs 0.000 title 1
- 239000012217 radiopharmaceutical Substances 0.000 title 1
- 230000002799 radiopharmaceutical effect Effects 0.000 title 1
- 239000002738 chelating agent Substances 0.000 abstract 4
- 230000008878 coupling Effects 0.000 abstract 3
- 238000010168 coupling process Methods 0.000 abstract 3
- 238000005859 coupling reaction Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 3
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000010668 complexation reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000002390 hyperplastic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención provee un método para la formación de un complejo de tono dirigido a tejido, en donde dicho método comprende; a) formar un quelante octadentado que comprende cuatro porciones hidroxipiridinona (HOPO) sustituidas en la posición N con un grupo C1-C3alquilo, y una porción de acoplamiento que termina en un grupo ácido carboxilico; b) acoplar dicho quelante octadentado a por lo menos un péptido o proteína de direccionamiento a tejido que comprende por lo menos una porción amina por medio de por lo menos un reactivo de acoplamiento de amida para generar así un quelante de direccionamiento a tejido; y c) poner en contacto dicho quelante de direccionamiento a tejido con una solución acuosa que comprende un ion de por lo menos un isótopo de tono emisor alfa. Un método de tratamiento de una enfermedad neoplásica o hiperplásica que comprende la administración de dicho complejo de tono dirigido a tejido, así como también se proveen el complejo y formulaciones farmacéuticas correspondientes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422512 | 2014-12-17 | ||
| PCT/EP2015/079773 WO2016096843A1 (en) | 2014-12-17 | 2015-12-15 | Radio-pharmaceutical complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017008093A true MX2017008093A (es) | 2018-02-09 |
| MX384088B MX384088B (es) | 2025-03-14 |
Family
ID=54884033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008093A MX384088B (es) | 2014-12-17 | 2015-12-15 | Complejos radiofarmacéuticos. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20170340759A1 (es) |
| EP (1) | EP3233137A1 (es) |
| JP (2) | JP6821569B2 (es) |
| KR (1) | KR20170094223A (es) |
| CN (1) | CN107278155B (es) |
| AR (1) | AR103063A1 (es) |
| AU (2) | AU2015367722A1 (es) |
| BR (1) | BR112017012841A2 (es) |
| CA (1) | CA2970841A1 (es) |
| CL (1) | CL2017001592A1 (es) |
| CO (1) | CO2017005975A2 (es) |
| CR (1) | CR20170256A (es) |
| CU (1) | CU24493B1 (es) |
| DO (1) | DOP2017000143A (es) |
| EA (1) | EA201791350A9 (es) |
| EC (1) | ECSP17038089A (es) |
| IL (1) | IL252244B (es) |
| JO (1) | JOP20150319B1 (es) |
| MA (1) | MA41176A (es) |
| MX (1) | MX384088B (es) |
| MY (1) | MY194190A (es) |
| NI (1) | NI201700076A (es) |
| PE (2) | PE20171181A1 (es) |
| PH (1) | PH12017501125A1 (es) |
| SG (1) | SG11201704917XA (es) |
| TN (1) | TN2017000255A1 (es) |
| TW (1) | TWI654179B (es) |
| UA (1) | UA125369C2 (es) |
| UY (1) | UY36453A (es) |
| WO (1) | WO2016096843A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018011629A (es) * | 2016-03-24 | 2019-03-14 | Bayer Pharma AG | Complejos radiofarmaceuticos. |
| CU20180149A7 (es) * | 2016-06-10 | 2019-07-04 | Bayer As | Complejos radio-farmacéuticos |
| CA3054248A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| ES2992988T3 (en) | 2017-03-30 | 2024-12-20 | Univ Cornell | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| EP3843743A1 (en) | 2018-08-28 | 2021-07-07 | Bayer AS | Combination of pi3k-inhibitors and targeted thorium conjugates |
| CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| US20220118123A1 (en) | 2019-02-22 | 2022-04-21 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| WO2021013978A1 (en) | 2019-07-25 | 2021-01-28 | Bayer As | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| MX2023008628A (es) | 2021-01-22 | 2023-09-22 | Bayer Ag | Anticuerpos lrrc15 y conjugados de los mismos. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158804B2 (en) * | 2007-01-11 | 2012-04-17 | Ge Healthcare As | Chelating agents |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2015
- 2015-12-14 MA MA041176A patent/MA41176A/fr unknown
- 2015-12-15 CR CR20170256A patent/CR20170256A/es unknown
- 2015-12-15 SG SG11201704917XA patent/SG11201704917XA/en unknown
- 2015-12-15 EP EP15813024.5A patent/EP3233137A1/en active Pending
- 2015-12-15 JP JP2017532833A patent/JP6821569B2/ja active Active
- 2015-12-15 PE PE2017001093A patent/PE20171181A1/es unknown
- 2015-12-15 PE PE2022002504A patent/PE20230829A1/es unknown
- 2015-12-15 AU AU2015367722A patent/AU2015367722A1/en not_active Abandoned
- 2015-12-15 CN CN201580069545.0A patent/CN107278155B/zh active Active
- 2015-12-15 UA UAA201707516A patent/UA125369C2/uk unknown
- 2015-12-15 MX MX2017008093A patent/MX384088B/es unknown
- 2015-12-15 CU CU2017000082A patent/CU24493B1/es unknown
- 2015-12-15 CA CA2970841A patent/CA2970841A1/en active Pending
- 2015-12-15 US US15/537,127 patent/US20170340759A1/en not_active Abandoned
- 2015-12-15 TN TN2017000255A patent/TN2017000255A1/en unknown
- 2015-12-15 BR BR112017012841A patent/BR112017012841A2/pt not_active Application Discontinuation
- 2015-12-15 MY MYPI2017702228A patent/MY194190A/en unknown
- 2015-12-15 EA EA201791350A patent/EA201791350A9/ru unknown
- 2015-12-15 WO PCT/EP2015/079773 patent/WO2016096843A1/en not_active Ceased
- 2015-12-15 KR KR1020177016311A patent/KR20170094223A/ko not_active Withdrawn
- 2015-12-16 JO JOP/2015/0319A patent/JOP20150319B1/ar active
- 2015-12-17 TW TW104142567A patent/TWI654179B/zh active
- 2015-12-17 AR ARP150104130A patent/AR103063A1/es not_active Application Discontinuation
- 2015-12-17 UY UY0001036453A patent/UY36453A/es not_active Application Discontinuation
-
2017
- 2017-05-11 IL IL252244A patent/IL252244B/en active IP Right Grant
- 2017-06-15 PH PH12017501125A patent/PH12017501125A1/en unknown
- 2017-06-16 CO CONC2017/0005975A patent/CO2017005975A2/es unknown
- 2017-06-16 CL CL2017001592A patent/CL2017001592A1/es unknown
- 2017-06-16 NI NI201700076A patent/NI201700076A/es unknown
- 2017-06-16 DO DO2017000143A patent/DOP2017000143A/es unknown
- 2017-06-19 EC ECIEPI201738089A patent/ECSP17038089A/es unknown
-
2021
- 2021-01-05 JP JP2021000454A patent/JP7160961B2/ja active Active
- 2021-01-15 US US17/150,811 patent/US20210322583A1/en not_active Abandoned
- 2021-04-29 AU AU2021202665A patent/AU2021202665B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017008093A (es) | Complejos radiofarmaceuticos. | |
| BR112018075554A2 (pt) | complexos radiofarmacêuticos | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| EA201892119A1 (ru) | Лекарственный препарат, полученный путем комбинирования агониста fxr и arb | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
| MX2017003121A (es) | Formulaciones de anticuerpos. | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| CL2018002695A1 (es) | Complejos radiofarmacéuticos | |
| EA201990093A1 (ru) | Двухкомпонентная композиция | |
| EA201692045A1 (ru) | Производное фенантролинфосфоновой кислоты и способ его получения и применения | |
| AR102149A1 (es) | Anticuerpos dirigidos contra ticagrelor y métodos para su uso |